Who are ARGX-113's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IV efgartigimod, Nipocalimab SC-LIV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/argx-113.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ARGX-113 — Competitive Intelligence Brief

ARGX-113 (ARGX-113) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FcRn inhibitor. Area: Immunology.

phase 3 FcRn inhibitor FcRn (neonatal Fc receptor) Immunology Biologic Live · refreshed every 30 min

Target snapshot

ARGX-113 (ARGX-113) — argenx. ARGX-113 is a monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ARGX-113 TARGET	ARGX-113	argenx	phase 3	FcRn inhibitor	FcRn (neonatal Fc receptor)
IV efgartigimod	IV efgartigimod	Rambam Health Care Campus	marketed	FcRn inhibitor	Neonatal Fc receptor (FcRn)
Nipocalimab SC-LIV	Nipocalimab SC-LIV	Janssen Research & Development, LLC	phase 3	FcRn inhibitor	Neonatal Fc receptor (FcRn)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FcRn inhibitor class)

Janssen Research & Development, LLC · 1 drug in this class
Rambam Health Care Campus · 1 drug in this class
argenx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARGX-113 — Competitive Intelligence Brief. https://druglandscape.com/ci/argx-113. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab